The Inventing Press

WEST PHARMACEUTICAL SERVICES INC

Financial highlights

MetricFY 12/31/25FY 12/31/24FY 12/31/23FY 12/31/22FY 12/31/21
Income Statement
Revenue$3.1B$2.9B$2.9B$2.9B$2.8B
Cost of revenue$2.0B$1.9B$1.8B$1.8B$1.7B
Gross profit$1.1B$998.5M$1.1B$1.1B$1.2B
Selling, general & administrative$393.6M$338.5M$353.4M$316.9M$362.8M
Research and development$74.3M$69.1M$68.4M$58.5M$52.8M
Operating income$584.9M$569.9M$676.0M$734.0M$752.3M
Interest expense$500,000$3.0M$9.0M$7.9M$8.2M
Pretax income$600.9M$585.5M$698.0M$679.9M$748.9M
Income tax expense$121.6M$107.5M$122.3M$114.7M$107.2M
Net income$493.7M$492.7M$593.4M$585.9M$661.8M
Balance Sheet
Cash and equivalents$791.3M$484.6M$853.9M$894.3M$762.6M
Current assets$2.0B$1.5B$1.9B$1.9B$1.7B
Total assets$4.3B$3.6B$3.8B$3.6B$3.3B
Current liabilities$654.9M$550.4M$671.8M$519.0M$594.1M
Total liabilities$1.1B$961.1M$948.5M$931.9M$978.4M
Total debt$203.0M$203.0M$207.0M$209.2M$253.5M
Stockholders' equity$3.2B$2.7B$2.9B$2.7B$2.3B
Cash Flow Statement
Cash from operations$754.8M$653.4M$776.5M$724.0M$584.0M
Depreciation and amortization$171.4M$155.4M$137.3M$120.6M$122.3M
Stock-based compensation$23.8M$18.7M$23.3M$23.7M$37.5M
Capital expenditure$285.9M$377.0M$362.0M$284.6M$253.4M
Free cash flow$468.9M$276.4M$414.5M$439.4M$330.6M
Dividends paid$61.2M$59.1M$57.0M$54.1M$51.1M
Share repurchases$134.0M$560.9M$438.3M$202.8M$137.1M
Impairments$11.7M$7.3M$9.6M$6.2M$5.6M

Shares outstanding 70.6M · Free float 92.8%

Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.